Nutri Pharmaceuticals Research, Inc. Provides Company Update
16 7월 2007 - 9:00PM
Business Wire
Nutri Pharmaceuticals Research, Inc. (Pink Sheets: NRPR) recently
announced First Quarter 2007 results of approximately $500,000 in
revenues and $132,000 in earnings. The results reflect new
marketing strategies, introduction of unique products to different
markets and growing popularity of their powders for increasing
manufacturing demands. These factors should continue to allow for
significantly higher sales and earnings in future quarters with a
large increase in its stock price. Nutri Pharmaceuticals Research,
Inc., www.o2pus.com, provides a wide range of powdered oils for
functional food, food supplement, pharmaceutical, cosmetic, pet
food and animal feed applications. The company is one of a select
few to be awarded the prestigious Nutrition Business Journal
"Product Merit Award" for its patent-pending O2P� Powderization
process. The patent-pending process converts most edible oils,
gels, pastes and other viscous fluids into a free-flowing powder
without affecting the isomeric structure, fatty acid profile,
color, taste or aroma of the base oil or fluids. Along with other
exciting products the company produces, possibly the most exciting
and potentially large sales potentials exist in producing oil to
powder from fish oil and flaxseeds when added to food products
increases the omega 3 fats in the body which is currently one�of
the fastest growing areas of the health food industry. The company
is a leader in this area and with other products could provide
large orders and significant sales and earnings in future years.
Forward-looking statements All statements contained in this Press
Release, other than statements of historical facts, that address
future activities, events or developments are forward-looking
statements, including, but not limited to, statements containing
the words "believe," "anticipate," "expect" and words of similar
import. These statements are based on certain assumptions and
analyses made by us in light of our experience and our assessment
of historical trends, current conditions and expected future
developments as well as other factors we believe are appropriate
under the circumstances. However, whether actual results will
conform to the expectations and predictions of management is
subject to a number of risks and uncertainties that may cause
actual results to differ materially. Such risks include, among
others, the following: international, national and local general
economic and market conditions: our ability to sustain, manage or
forecast our growth; raw material costs and availability; new
product development and introduction; existing government
regulations and changes in, or the failure to comply with,
government regulations; adverse publicity; competition; the loss of
significant customers or suppliers; fluctuations and difficulty in
forecasting operating results; changes in business strategy or
development plans; business disruptions; the ability to attract and
retain qualified personnel; the ability to protect technology; and
other factors referenced in this and previous disclosures.
Consequently, all of the forward-looking statements made in this
Press Release are qualified by these cautionary statements and
there can be no assurance that the actual results anticipated by
management will be realized or, even if substantially realized,
that they will have the expected results or consequences to or
effects on our business operations.
Nutri Pharmaceuticals Re... (PK) (USOTC:NRPR)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Nutri Pharmaceuticals Re... (PK) (USOTC:NRPR)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
Nutri Pharmaceuticals Research Inc (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Nutri Pharmaceuticals Research, Inc. News Articles